Life Science News

Sixth Wave Innovations Inc. is pleased to announce that it has entered into a non-binding letter of intent with Halucenex Life Sciences Inc. to explore a collaboration for the separation of compounds such as psilocybin, baeocystin, and others using molecularly imprinted polymers . The companies have agreed to negotiate in good faith toward reaching a definitive agreement which will govern the potential ...

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) ("Sixth Wave" or the "Company") is pleased to announce that it has entered into a non-binding letter of intent with Halucenex Life Sciences Inc. ("Halucenex") to explore a collaboration for the separation of compounds such as psilocybin, baeocystin, and others using molecularly imprinted polymers ("MIPs"). The companies have agreed to negotiate in good faith toward reaching a definitive agreement which will govern the potential collaboration. Under the terms contemplated by the LOI, Sixth Wave will utilize the basic design and operation of its Affinity™ cannabinoid purification system with molecularly imprinted polymers specifically designed for these target molecules.

About Halucenex Life Sciences Inc.

Halucenex is a life sciences development company with a focus on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine. Halucenex operates a 6000 sq. ft. medical facility in Windsor, Nova Scotia with 6 treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research. Halucenex intends to maintain control over all aspects of the product development process - mycological research, extraction technology, and synthetic formulation as well as drug delivery technologies, psychedelic-assisted psychotherapy and regulatory affairs. Halucenex has entered into an agreement further to which it will become a wholly-owned subsidiary of Creso Pharma Limited, subject to completion of due diligence and standard closing conditions.

About Creso Pharma Limited

Creso Pharma Limited brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our web site at: www.sixthwave.com.

ON BEHALF OF THE BOARD OF DIRECTORS

"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed "forward-looking statements" including statements regarding the planned execution of a definitive agreement with Halucenex. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80829

News Provided by Newsfile via QuoteMedia

NeonMind Biosciences

NeonMind Biosciences: Using Psychedelics as Treatment for Mental Health Disorders and Weight Management

NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF,FRA:6UF) has launched its campaign on the Investing News Network's Life Science and Psychedelics channels.

NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF,FRA:6UF) is a drug development and healthcare company pioneering innovative ways to bring transformational mental health treatments to market with a focus on psychedelics. The company aims to improve access to psychedelic treatments with two strategies:

  1. Establishing specialized mental health clinics that provide currently available treatments such as ketamine and esketamine and to provide other psychedelic treatments when approved.
  2. Focusing on drug development of novel psychedelic treatments focusing on their proprietary drug candidates to treat behavioral deficits in patients with weight management issues and obesity.

Medical mushrooms for psychedelic treatmentMedical mushrooms for psychedelic treatmentinvestingnews.com

Keep reading...Show less
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.

Universal Ibogaine engages Shayne Nyquvest as Capital Markets Advisor (CNW Group/Universal Ibogaine Inc.)

Mr. Nyquvest has extensive capital markets experience, with over 40 years involvement in aiding companies strategic fund-raising activities, in the mining, cannabis and other emerging industries.  He served as the former Executive Vice-President of investment banking firm Mackie Research Capital (where he worked from June 2015 to July 2018 ) and a was founding member of Canaccord Genuity Group, where he worked as a Senior Investment Advisor from 1993 to 2013.

Mr. Nyquvest co-founded UI in early 2018, after personally seeing the transformational effects and potential of ibogaine and was involved in UI's early-stage development until mid-2021.  His vision has been to see this innovative, plant-based treatment adopted by the mainstream medical community as a solution to helping break the opioid epidemic and other addictions.

Nick Karos , UI CEO noted "we are pleased to have Shayne re-engaged in our strategic, business development goals.  He has an extensive network in the investment community and was instrumental in UI's early-stage financing and research activities.  We continue to advance our planned Health Canada clinical trials application for the use of ibogaine in opioid use disorder and expect to provide additional updates on this in the near future."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-retains-shayne-nyquvest-as-capital-markets-advisor-301536451.html

SOURCE Universal Ibogaine Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

(TheNewswire)

Universal Ibogaine Inc.

Calgary, AB TheNewswire - April 21, 2022 Universal Ibogaine Inc. ( TSXV:IBO ) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that Marilyn Loewen Mauritz has resigned as a member of the UI Board of Directors to pursue other opportunities.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Billy Goat Brands

Billy Goat Brands Joins SeaLegacy's Good Ocean Supporting Critical Ocean Conservation Work

  • The Company's Commitment is Aligned with its Focus on the Oceans and Proactive Attentiveness to the Growing Consumer Demand for Accountability in how Products are Made, Sold and Marketed
  • SeaLegacy a Global Non-Profit Using the Power of Media and Storytelling to Amplify Ocean Solutions
  • Funds Raised Through SeaLegacy's Good Ocean Support Impact Grants to Organizations Leading On-the-Ground Projects that Conserve Oceans While Building a More Just and Equitable Planet
  • SeaLegacy and its Co-Founders Boast a Combined Audience of Over 10 Million Instagram Followers

Billy Goat Brands Ltd. ("GOAT" or the "Company") (CSE: GOAT) (OTCQB: BGTTF) (FRA: 26B), a venture capital platform focused on identifying, sponsoring and incubating high-potential companies in the ocean economy, is pleased to announce a one-year commitment to SeaLegacy (" SeaLegacy ") through The Good Ocean (" Good Ocean " or the " Program "). SeaLegacy is an organization that uses a variety of collaborations, experts and the latest digital and social technologies to aid in the building of a healthy future for oceans across the world. The Good Ocean is a community of businesses that supports SeaLegacy's mission and aligns with its values to create a better planet. GOAT is dedicated to making a difference when it comes to the sustainability of oceans through sustainable commerce, which is reinforced by its sponsorship of the Program.

The Company will be acknowledged on SeaLegacy's established social media network and website, be exposed to exclusive networking opportunities, have access to visual assets provided by SeaLegacy and the Program, as well as work with the communications team to create other bespoke amplification opportunities. SeaLegacy has a wide reach with 2.4 million followers on its @sealegacy Instagram account, while its Co-Founders Cristina Mittermeier and Paul Nicklen have 1.5 million and 7.3 million followers on their @mitty and @paulnicklen Instagram accounts, respectively. Therefore, the SeaLegacy team is creating ocean conservation awareness on an unmatched scale.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
How to Invest in Plant-based Foods

How to Invest in Plant-based Foods

Growing consumer concerns about health, ethical food and climate change are creating opportunities to invest in the burgeoning plant-based foods market.

The global plant-based foods market is projected to expand at a compound annual growth rate of 18.6 percent between 2020 and 2030 to reach more than US$162 billion, as per Bloomberg Intelligence.

This major expansion is being fueled in large part by increasing consumer demand for plant-based alternatives to meat and dairy. Calls from buyers for transparency and ethical practices across the food supply chain are also becoming louder and buoying interest in plant-based options.

Keep reading...Show less
UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

Universal Ibogaine Inc. (TSXV: IBO) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre (" Kelburn ") due to an on-site flooding issue.

Universal Ibogaine Update on Kelburn Operations (CNW Group/Universal Ibogaine Inc.)

Kelburn is UI's addiction treatment site operating near Winnipeg, Manitoba , and which experienced abnormally high winter snowfall conditions, resulting in high current groundwater levels arising from spring melt conditions. Kelburn is currently assessing options for continuation of in-process patient treatment, and remediation of damages, which will fall under Kelburn's property and business interruption insurance coverage, subject to policy limits. The timing for remediation and ultimate re-opening of operations at Kelburn is not determinable, but will likely require a minimum of 2 to 3 months.

Nick Karos (CEO) noted "this is of course an unfortunate unforeseen event, and our first priority is to ensure the continuity of ongoing care of our patient group. The extent of damage will hopefully be contained to a portion of the basement, and allow us to resume on-site operations in a reasonable time frame."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur. The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof. UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Related Links

Universal Ibogaine

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-provides-update-on-kelburn-recovery-center-operations-301520593.html

SOURCE Universal Ibogaine Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2022/07/c7462.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×